The Alberta Heart Failure Etiology and Analysis Research Team (HEART) study

Justin A Ezekowitz, Harald Becher, Israel Belenkie, Alexander M Clark, Henry J Duff, Matthias G Friedrich, Mark J Haykowsky, Jonathan G Howlett, Zamaneh Kassiri, Padma Kaul, Daniel H Kim, Merril L Knudtson, Peter E Light, Gary D Lopaschuk, Finlay A McAlister, Michelle L Noga, Gavin Y Oudit, D Ian Paterson, Hude Quan, Richard Schulz, Richard B Thompson, Sarah G Weeks, Todd J Anderson, Jason R B Dyck, Justin A Ezekowitz, Harald Becher, Israel Belenkie, Alexander M Clark, Henry J Duff, Matthias G Friedrich, Mark J Haykowsky, Jonathan G Howlett, Zamaneh Kassiri, Padma Kaul, Daniel H Kim, Merril L Knudtson, Peter E Light, Gary D Lopaschuk, Finlay A McAlister, Michelle L Noga, Gavin Y Oudit, D Ian Paterson, Hude Quan, Richard Schulz, Richard B Thompson, Sarah G Weeks, Todd J Anderson, Jason R B Dyck

Abstract

Background: Nationally, symptomatic heart failure affects 1.5-2% of Canadians, incurs $3 billion in hospital costs annually and the global burden is expected to double in the next 1-2 decades. The current one-year mortality rate after diagnosis of heart failure remains high at >25%. Consequently, new therapeutic strategies need to be developed for this debilitating condition.

Methods/design: The objective of the Alberta HEART program (http://albertaheartresearch.ca) is to develop novel diagnostic, therapeutic and prognostic approaches to patients with heart failure with preserved ejection fraction. We hypothesize that novel imaging techniques and biomarkers will aid in describing heart failure with preserved ejection fraction. Furthermore, the development of new diagnostic criteria will allow us to: 1) better define risk factors associated with heart failure with preserved ejection fraction; 2) elucidate clinical, cellular and molecular mechanisms involved with the development and progression of heart failure with preserved ejection fraction; 3) design and test new therapeutic strategies for patients with heart failure with preserved ejection fraction. Additionally, Alberta HEART provides training and education for enhancing translational medicine, knowledge translation and clinical practice in heart failure. This is a prospective observational cohort study of patients with, or at risk for, heart failure. Patients will have sequential testing including quality of life and clinical outcomes over 12 months. After that time, study participants will be passively followed via linkage to external administrative databases. Clinical outcomes of interest include death, hospitalization, emergency department visits, physician resource use and/or heart transplant. Patients will be followed for a total of 5 years.

Discussion: Alberta HEART has the primary objective to define new diagnostic criteria for patients with heart failure with preserved ejection fraction. New criteria will allow for targeted therapies, diagnostic tests and further understanding of the patients, both at-risk for and with heart failure.

Trial registration: ClinicalTrials.gov NCT02052804.

Figures

Figure 1
Figure 1
Alberta HEART study design.
Figure 2
Figure 2
Alberta HEART adjudication process.

References

    1. Ezekowitz JA, Kaul P, Bakal JA, Quan H, McAlister FA. Trends in heart failure care: has the incident diagnosis of heart failure shifted from the hospital to the emergency department and outpatient clinics? Eur J Heart Fail. 2011;13:142–147. doi: 10.1093/eurjhf/hfq185.
    1. Johansen H, Strauss B, Arnold JMO, Moe G, Liu P. On the rise: The current and projected future burden of congestive heart failure hospitalization in Canada. Can J Cardiol. 2003;19:430–435.
    1. Redfield MM, Jacobsen SJ, Burnett JC Jr, Mahoney DW, Bailey KR, Rodeheffer RJ. Burden of systolic and diastolic ventricular dysfunction in the community. JAMA. 2003;289:194–202. doi: 10.1001/jama.289.2.194.
    1. Bhatia RS, Tu JV, Lee DS, Austin PC, Fang J, Haouzi A, Gong Y, Liu PP. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med. 2006;355:260–269. doi: 10.1056/NEJMoa051530.
    1. Ezekowitz JA, Bakal JA, Kaul P, Westerhout CM, Armstrong PW. Acute heart failure in the emergency department: short and long-term outcomes of elderly patients with heart failure. Eur J Heart Fail. 2008;10:308–314. doi: 10.1016/j.ejheart.2008.01.014.
    1. Stewart AL, Greenfield S, Hays RD, Wells K, Rogers WH, Berry SD, McGlynn EA, Ware JE. Functional status and well-being of patients with chronic conditions. Results from the Medical Outcomes Study. JAMA. 1989;262:907–913. doi: 10.1001/jama.1989.03430070055030.
    1. McKelvie RS, Moe GW, Cheung A, Costigan J, Ducharme A, Estrella-Holder E, Ezekowitz JA, Floras J, Giannetti N, Grzeslo A, Harkness K, Heckman GA, Howlett JG, Kouz S, Leblanc K, Mann E, O'Meara E, Rajda M, Rao V, Simon J, Swiggum E, Zieroth S, Arnold JMO, Ashton T, D'Astous M, Dorian P, Haddad H, Isaac DL, Leblanc M-H, Liu P. et al.The 2011 Canadian Cardiovascular Society heart failure management guidelines update: focus on sleep apnea, renal dysfunction, mechanical circulatory support, and palliative care. Can J Cardiol. 2011;27:319–338. doi: 10.1016/j.cjca.2011.03.011.
    1. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Drazner MH, Fonarow GC, Geraci SA, HORWICH T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJV, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WHW, Tsai EJ, Wilkoff BL. American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013;128:e240–e327.
    1. Lindenfeld J, Albert NM, Boehmer JP, Collins SP, Ezekowitz JA, Givertz MM, Katz SD, Klapholz M, Moser DK, Rogers JG, Starling RC, Stevenson WG, Tang WHW, Teerlink JR, Walsh MN. Heart Failure Society of America. Comprehensive Heart Failure Practice Guideline. J Card Fail. 2010;2010:e1–e194.
    1. Ezekowitz JA, Lee DS, Tu JV, Newman AM, McAlister FA. Comparison of One-Year Outcome (Death and Rehospitalization) in Hospitalized Heart Failure Patients With Left Ventricular Ejection Fraction >50% Versus Those With Ejection Fraction. Am J Cardiol. 2008;102:79–83. doi: 10.1016/j.amjcard.2008.02.102.
    1. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006;355:251–259. doi: 10.1056/NEJMoa052256.
    1. McMurray JJV, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Sanchez MAG, Jaarsma T, Køber L, Lip GYH, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Rønnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A, Bax JJ, Baumgartner H. Authors/Task Force Members et al.ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012;33:1787–1847.
    1. McKelvie RS, Moe GW, Ezekowitz JA, Heckman GA, Costigan J, Ducharme A, Estrella-Holder E, Giannetti N, Grzeslo A, Harkness K, Howlett JG, Kouz S, Leblanc K, Mann E, Nigam A, O'Meara E, Rajda M, Steinhart B, Swiggum E, Le VV, Zieroth S, Arnold JMO, Ashton T, D'Astous M, DORIAN P, Haddad H, Isaac DL, Leblanc MH, Liu P, Rao V, The 2012 Canadian Cardiovascular Society Heart Failure Management Guidelines Update: Focus on Acute and Chronic Heart Failure. CJCA. 2012. pp. 1–14.
    1. Paulus WJ, Tschöpe C, Sanderson JE, Rusconi C, Flachskampf FA, Rademakers FE, Marino P, Smiseth OA, De Keulenaer G, Leite-Moreira AF, Borbély A, Edes I, Handoko ML, Heymans S, Pezzali N, Pieske B, Dickstein K, Fraser AG, Brutsaert DL. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J. 2007;28:2539–2550. doi: 10.1093/eurheartj/ehm037.
    1. Vasan RS, Levy D. Defining diastolic heart failure: a call for standardized diagnostic criteria. Circulation. 2000;101:2118–2121. doi: 10.1161/01.CIR.101.17.2118.
    1. Zile MR, Gaasch WH, Carroll JD, Feldman MD, Aurigemma GP, Schaer GL, Ghali JK, Liebson PR. Heart Failure With a Normal Ejection Fraction: Is Measurement of Diastolic Function Necessary to Make the Diagnosis of Diastolic Heart Failure? Circulation. 2001;104:779–782. doi: 10.1161/hc3201.094226.
    1. Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, Anderson S, Donovan M, Iverson E, Staiger C, Ptaszynska A. I-PRESERVE Investigators. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. 2008;359:2456–2467. doi: 10.1056/NEJMoa0805450.
    1. Cleland JGF. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J. 2006;27:2338–2345. doi: 10.1093/eurheartj/ehl250.
    1. Zile MR. New Concepts in Diastolic Dysfunction and Diastolic Heart Failure: Part I: Diagnosis, Prognosis, and Measurements of Diastolic Function. Circulation. 2002;105:1387–1393. doi: 10.1161/hc1102.105289.
    1. Bossuyt PM. Comparative accuracy: assessing new tests against existing diagnostic pathways. BMJ. 2006;332:1089–1092. doi: 10.1136/bmj.332.7549.1089.
    1. Sackett DL, Haynes RB. The architecture of diagnostic research. BMJ. 2002;324:539–541. doi: 10.1136/bmj.324.7336.539.
    1. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, Lijmer JG, Moher D, Rennie D, de Vet HCW. Standards for Reporting of Diagnostic Accuracy. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. BMJ. 2003;326:41–44. doi: 10.1136/bmj.326.7379.41.
    1. Whiting PF, Rutjes AWS, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, Leeflang MMG, Sterne JAC, Bossuyt PMM. QUADAS-2 Group: QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011;155:529–536. doi: 10.7326/0003-4819-155-8-201110180-00009.
    1. Zile MR, Baicu CF, Gaasch WH. Diastolic heart failure–abnormalities in active relaxation and passive stiffness of the left ventricle. N Engl J Med. 2004;350:1953–1959. doi: 10.1056/NEJMoa032566.
    1. Westermann D, Kasner M, Steendijk P, Spillmann F, Riad A, Weitmann K, Hoffmann W, Poller W, Pauschinger M, Schultheiss H-P, Tschöpe C. Role of left ventricular stiffness in heart failure with normal ejection fraction. Circulation. 2008;117:2051–2060. doi: 10.1161/CIRCULATIONAHA.107.716886.
    1. Hay I, Rich J, Ferber P, Burkhoff D, Maurer MS. Role of impaired myocardial relaxation in the production of elevated left ventricular filling pressure. Am J Physiol Heart Circ Physiol. 2005;288:H1203–H1208.
    1. Redfield MM, Jacobsen SJ, Borlaug BA, Rodeheffer RJ, Kass DA. Age- and Gender-Related Ventricular-Vascular Stiffening. Circulation. 2005;112(15):2254–2262. doi: 10.1161/CIRCULATIONAHA.105.541078.
    1. Borlaug BA, Kass DA. Ventricular-vascular interaction in heart failure. Cardiol Clin. 2011;29:447–459. doi: 10.1016/j.ccl.2011.06.004.
    1. Poole DC, Hirai DM, Copp SW, Musch TI. Muscle oxygen transport and utilization in heart failure: implications for exercise (in)tolerance. Am J Physiol Heart Circ Physiol. 2012;302:H1050–H1063. doi: 10.1152/ajpheart.00943.2011.
    1. Haykowsky M, Brubaker P, Kitzman D. Role of physical training in heart failure with preserved ejection fraction. Curr Heart Fail Rep. 2012;9:101–106. doi: 10.1007/s11897-012-0087-7.
    1. Agostoni P, Cattadori G, Apostolo A, Contini M, Palermo P, Marenzi G, Wasserman K. Noninvasive Measurement of Cardiac Output During Exercise by Inert Gas Rebreathing Technique: A New Tool for Heart Failure Evaluation. J Am Coll Cardiol. 2005;46:1779–1781. doi: 10.1016/j.jacc.2005.08.005.
    1. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature. 1980;288(5789):373–376. doi: 10.1038/288373a0.
    1. Lerman A. Endothelial Function: Cardiac Events. Circulation. 2005;111:363–368. doi: 10.1161/01.CIR.0000153339.27064.14.
    1. Haykowsky MJ, Brubaker PH, Morgan TM, Kritchevsky S, Eggebeen J, Kitzman DW. Impaired Aerobic Capacity and Physical Functional Performance in Older Heart Failure Patients With Preserved Ejection Fraction: Role of Lean Body Mass. J Gerontol A: Biol Med Sci. 2013;68:968–975. doi: 10.1093/gerona/glt011.
    1. Kitzman DW, Brubaker PH, Herrington DM, Morgan TM, Stewart KP, Hundley WG, Abdelhamed A, Haykowsky MJ. Effect of Endurance Exercise Training on Endothelial Function and Arterial Stiffness in Older Patients With Heart Failure and Preserved Ejection Fraction: A Randomized, Controlled, Single-Blind Trial. J Am Chem Soc. 2013;62:584–592.
    1. Akiyama E, Sugiyama S, Matsuzawa Y, Konishi M, Suzuki H, Nozaki T, Ohba K, Matsubara J, Maeda H, Horibata Y, Sakamoto K, Sugamura K, Yamamuro M, Sumida H, Kaikita K, Iwashita S, Matsui K, Kimura K, Umemura S, Ogawa H. Incremental Prognostic Significance of Peripheral Endothelial Dysfunction in Patients With Heart Failure With Normal Left Ventricular Ejection Fraction. J Am Chem Soc. 2012;60:1778–1786.
    1. Anderson TJ, Charbonneau F, Buithieu J, Rose MS. Microvascular Function Predicts Cardiovascular Events in Primary Prevention Long-Term Results From the Firefighters and Their Endothelium (FATE) Study. Circulation. 2011;123(2):163–169. doi: 10.1161/CIRCULATIONAHA.110.953653.
    1. Anderson TJ. Prognostic significance of brachial flow-mediated vasodilation. Circulation. 2007;115(18):2373–2375. doi: 10.1161/CIRCULATIONAHA.107.697045.
    1. Braunwald E. Biomarkers in Heart Failure. N Engl J Med. 2008;358:2148–2159. doi: 10.1056/NEJMra0800239.
    1. Gerszten RE, Wang TJ. The search for new cardiovascular biomarkers. Nature. 2008;451:949–952. doi: 10.1038/nature06802.
    1. Roach DE, Morck ML, Sheldon RS, Duff HJ. Auto-entrainment risk assessment in heart failure. Circ Arrhythm Electrophysiol. 2013;6:129–136. doi: 10.1161/CIRCEP.112.971986.
    1. Kaul P, McAlister FA, Ezekowitz JA, Bakal JA, Curtis LH, Quan H, Knudtson ML, Armstrong PW. Resource use in the last 6 months of life among patients with heart failure in Canada. Arch Intern Med. 2011;171:211–217. doi: 10.1001/archinternmed.2010.365.
    1. Ezekowitz JA, van Walraven C, McAlister FA. Impact of specialist follow-up in outpatients with congestive heart failure. Can Med Assoc J. 2005;172:189–194. doi: 10.1503/cmaj.1032017.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться